Ireland - English - HPRA (Health Products Regulatory Authority)

zoetis belgium s.a. - inactivated leptospira borgpetersenii serovar hardjo type hardjobovis - suspension for injection - . - leptospira - cattle - immunological

Ireland - English - HPRA (Health Products Regulatory Authority)

intervet ireland limited - tetanus toxoid - suspension for injection - bovine - immunological - inactivated vaccine

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios hipra s.a. - mannheimia haemolytica biotype a, serotype a1, strain 2806, leukotoxoid, inactivated haemophilus sommus bailie strain - emulsion for injection - unknown - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia vaccines) - bovine - immunological - inactivated vaccine

United Kingdom - English - VMD (Veterinary Medicines Directorate)

laboratorios hipra sa - histophilus somni, mannheimia haemolytica - emulsion for injection - inactivated bacterial vaccine - cattle

European Union - English - EMA (European Medicines Agency)

ceva santé animale - inactivated coxiella burnetii vaccine, strain nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus., onset of immunity: not established., duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta., onset of immunity: not established., duration of immunity: one year after completion of the primary vaccination course.

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios hipra s.a. - mannheimia haemolytica biotype a, serotype a1 leukotoxoid; haemophilus somnus bailie strain, inactivated - emulsion for injection - . - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - cattle - immunological - inactivated vaccine

European Union - English - EMA (European Medicines Agency)

laboratorios hipra, s.a. - lipoteichoic acid from biofilm adhesion component of streptococcus uberis, strain 5616 - immunologicals for bovidae - cattle - for active immunisation of healthy cows and heifers to reduce the incidence of clinical intramammary infections caused by streptococcus uberis, to reduce the somatic cell count in streptococcus uberis positive quarter milk samples and to reduce milk production losses caused by streptococcus uberis intramammary infections.

United Kingdom - English - VMD (Veterinary Medicines Directorate)

laboratorios hipra sa - biofilm adhesion component (bac) of streptococcus uberis - emulsion for injection - inactivated bacterial vaccine - cattle

Ireland - English - HPRA (Health Products Regulatory Authority)

intervet ireland limited - salmonella dublin strain s342/70 formalin inactivated, salmonella typhimurium strain s341/70 formalin inactivated - suspension for injection - unknown - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia vaccines) - bovine - immunological - inactivated vaccine

European Union - English - EMA (European Medicines Agency)

laboratorios hipra s.a. - escherichia coli j5 inactivated, staphylococcus aureus (cp8) strain sp 140 inactivated, expressing slime-associated antigenic complex - immunologicals for bovidae - cattle (cows and heifers) - for herd immunisation of healthy cows and heifers, in dairy cattle herds with recurring mastitis problems, to reduce the incidence of sub-clinical mastitis and the incidence and the severity of the clinical signs of clinical mastitis caused by staphylococcus aureus, coliforms and coagulase-negative staphylococci.the full immunisation scheme induces immunity from approximately day 13 after the first injection until approximately day 78 after the third injection (equivalent to 130 days post-parturition).